The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice

Blood

Volumn 103, Issue 3, 2004, Pages 1069-1077

  Chand, Hitendra Singh ^b   Du, Xin ^b   Ma, Duan ^b   Inzunza, Hector David ^b   Kamei, Shintaro ^b   Foster, Donald ^b   Brodie, Steven ^b   Kisiel, Walter ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME PRECURSOR; MATRIX METALLOPROTEINASE; PLACENTA PROTEIN 5; PLASMIN; PLASMIN INHIBITOR; TRYPSIN; TRYPSIN INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INVASION; CARCINOGENESIS; CLINICAL PATHWAY; CONTROLLED STUDY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBROSARCOMA; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; MOUSE; MYELOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

EID: 1642459321     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-1930     Document Type: Article

References (52)

1. Dano K, Andreasen PA, Grondahl-Johnson J, Kristensen P, Nielsen LS, Skdver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139-266.
2. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 1995;73:161-195.
3. Iino M, Foster DC, Kisiel W. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol. 1998;18:40-46.
4. Herman MP, Sukhova GK, Kisiel W, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest. 2001;107:1117-1126.
5. Rao CN, Liu YY, Peavey CL, Woodley DT. Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch Biochem Biophys. 1995;104:311-314.
6. Rao CN, Peavey CL, Liu YY, Lapiere JC, Woodley DT. Partial characterization of matrix-associated serine protease inhibitors from human skin cells. J Invest Dermatol. 1995;104:379-383.
7. Deng FM, Ding M, Lavker RM, Sun TT. Urothelial function reconsidered: a role in urinary protein secretion. Proc Natl Acad Sci U S A. 2001;98:154-159.
8. Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second tissue factor pathway inhibitor. Proc Natl Acad Sci U S A. 1994;91:3353-3357.
9. Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry. 1996;35:266-272.
10. Miyagi Y, Koshikawa N, Yasumitsu H, et al. cDNA cloning and mRNA expression of a serine protease inhibitor secreted by cancer cells: identification as placental 5 and tissue factor pathway inhibitor-2. J Biochem. 1994;116:939-942.
11. Rao CN, Reddy P, Liu YY, et al. Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch Biochem Biophys. 1996;335:45-52.
12. Kamei S, Petersen LC, Sprecher CA, Foster DC, Kisiel W. Inhibitory properties of human recombinant Arg24→Gln type-2 tissue factor pathway inhibitor (TFPI-2). Thromb Res. 1999;94:147-152.
13. Rao CN, Mohanam S, Puppala A, Rao JS. Regulation of proMMP-1 and proMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. Biochem Biophys Res Commun. 1999;255:94-99.
14. Izumi H, Takahashi C, Oh J, Noda M. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett. 2000;481:31-36.
15. Crawley JTB, Goulding DA, Ferreira V, Severs NJ, Lupu F. Expression and localization of tissue factor pathway inhibitor-2 in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 2002;22:218-224.
16. Rao CN, Cook B, Liu YY, et al. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33kDa MSPI. Int J Cancer. 1998;75:749-756.
17. Lane RD, Crissman RS, Ginn S. High efficiency fusion procedure for producing monoclonal antibodies against weak immunogens. Methods Enzymol. 1986;121:183-192.
18. Bernstein JL, Thompson WD, Casey G, et al. Comparison of techniques for the successful detection of BRCA1 mutations in fixed paraffin-embedded tissue. Cancer Epidemiol Biomarkers Prev. 2002;11:809-814.
19. Shih SC, Robinson GS, Perruzzi CA, et al. Molecular profiling of angiogenesis markers. Am J Pathol. 2002;161:35-41.
20. Konduri SD, Rao CN, Chandrasekar N, et al. A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. Oncogene. 2001;20:6938-6945.
21. Jin MS, Udagawa K, Miyagi E, et al. Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in-vitro and in-vivo. Gynecol Oncol. 2001;83:325-333.
22. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A. 1993;90:5021-5025.
23. Stahl A, Muller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 1994;54:3066-3071.
24. Min YH, Doyle VL, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996;56:2428-2433.
25. 2-macroglobulin secretion. Cell Regul. 1990;1:895-905.
26. Quax PHA, van Muijen GNP, Weening-Verhoff EJD, et al. Metastatic behavior of human melanoma cells in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor and urokinase-mediated degradation. J Cell Biol. 1991;115:191-199.
27. Reinartz J, Batria R, Boukamp P, Fusenig N, Kramer MD. Binding and activation of plasminogen at the surface of human keratinocytes. Exp Cell Res. 1993;208:197-208.
28. Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev. 1992;11:291-311.
29. Kramer MD, Reinartz J, Brunner G, Schirrmacher V. Plasmin in pericellular proteolysis and cellular invasion. Invasion Metastasis. 1994;14:210-222.
30. Tarui T, Majumdar M, Miles LA, Ruf W, Takada Y. Plasmin-induced migration of endothelial cells: a potential target for the anti-angiogenic action of angiostatin. J Biol Chem. 2002;277:33564-33570.
31. Soff GA, Sanderowitz J, Gately S, et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest. 1995;96:2593-2600.
32. Sawaji Y, Sato T, Takeuchi A, Hirata M, Ito A. Antiangiogenic action of hyperthermia by suppressing gene expression and production of tumor-derived vascular endothelial growth factor in vivo and in vitro. Br J Cancer. 2002;86:1597-1603.
33. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 2000;60:6253-6258.
34. Andre T, Kotelevets L, Vaillant JC, et al. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer. 2000;86:174-181.
35. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A. 1998;95:11709-11714.
36. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001;20:672-682.
37. Osawa Y, Nagaki M, Banno Y, et al. Tumor necrosis factor alpha-induced interleukin-8 production via NF-kappaB and phosphatidylinositol 3-kinase/Akt pathways inhibits cell apoptosis in human hepatocytes. Infect Immun. 2002;70:6294-6301.
38. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 2001;98:12485-12490.
39. Ekstrand AJ, Cao R, Bjorndahl M, et al. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci U S A. 2003;100:6033-6038.
40. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev. 2003;83:337-376.
41. Winn RA, Bremnes RM, Bemis L, et al. Gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene. 2002;21:7497-7506.
42. Zondag GC, Reynolds AB, Moolenaar WH. Receptor protein-tyrosine phosphatase RPTPmu binds to and dephosphorylates the catenin p120(ctn). J Biol Chem. 2000;275:11264-11269.
43. Ryniers F, Stove C, Goethals M, et al. Plasmin produces an E-cadherin fragment that stimulates cancer cell invasion. Biol Chem. 2002;383:159-165.
44. Nawrocki-Raby B, Gilles C, Polette M, et al. Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int J Cancer. 2003;105:790-795.
45. Lee YG, Macoska JA, Korenchuk S, Pienta KJ. MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia. 2002;4:291-294.
46. Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001;107:789-800.
47. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, Takahashi C. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev. 2003;22:167-175.
48. Takahashi C, Sheng Z, Horan TP, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A. 1998;95:13221-13226.
49. Mazzucchelli L. Protein S100A4: too long overlooked by pathologists? Am J Pathol. 2002;1601:7-13.
50. Yayoshi-Yamamoto S, Taniuchi I, Watanabe T. FRL, a novel formin-related protein, binds to Rac and regulates cell motility and survival of macrophages. Mol Cell Biol. 2000;20:6872-6881.
51. Bodner A, Toth PT, Oh SB, et al. CD4 dependence of gp 120IIIB-CXCR4 interaction is cell-type specific. J Neuroimmunol. 2003;140:1-12.
52. Chau BN, Cheng EH, Kerr DA, Hardwick JM. Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell. 2000;6:31-40.